Catalysts for Glyxambi
21 tracked
Oct 24, 2025
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Oct 30, 2023
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Oct 13, 2022
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Mar 21, 2022
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jun 11, 2021
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jun 11, 2021
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Mar 30, 2020
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jan 24, 2020
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jul 3, 2019
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jul 1, 2019
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Oct 26, 2018
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Dec 13, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Aug 10, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Aug 10, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Mar 14, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Dec 23, 2016
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Dec 23, 2016
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jul 8, 2016
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Dec 4, 2015
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Aug 28, 2015
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Jan 30, 2015
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→